Figure 1. BGE-102 resulted in significant, dose-dependent increases in overall weight loss compared to placebo in a diet-induced obesity mouse model. Group size: n=8–10 per group. BGE-102 75 mpk vs. obese control, Day 27: p<0.0001. Note: BGE-102 is 150–250x more potent in human microglia, the target cell in the brain, compared to mouse microglia, consistent with <50 mg predicted daily dose.
Figure 1. BGE-102 resulted in significant, dose-dependent increases in overall weight loss compared to placebo in a diet-induced obesity mouse model. Group size: n=8–10 per group. BGE-102 75 mpk vs. obese control, Day 27: p<0.0001. Note: BGE-102 is 150–250x more potent in human microglia, the target cell in the brain, compared to mouse microglia, consistent with <50 mg predicted daily dose.